AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
← catalyst calendarNCT07509307 · readout in 726 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
400estimated
Sites
81
Countries
Australia, Bulgaria, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-20 | actual | When the study began enrolling |
| Primary completion | 2028-08-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Osteoarthritis, Knee
Interventions
- Drug: NNC0487-0111
- Drug: Placebo (matched to NNC0487-0111)
Primary outcomes
what the primary-completion date above is the date OFRelative change in body weight
measured From baseline (week 0) to week 80
Change in Western Ontario and McMaster Universities Osteoarthritis Index Numerical Rating Scale (NRS) 3.1 (24-hour) (WOMAC) pain score
measured From baseline (week 0) to week 80
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed